CHI3L1, an indicator of the inflammatory and immune status of the body, has been shown to be associated with the prognosis of patients with malignant tumors such as colon, breast, ovarian, and non-small cell lung cancers (25–29). Here, CHI3L1 is linked to non-small cell lung carcinoma.